- The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

In a pioneering discovery, Huntsman Cancer Institute researchers have found that obesity may increase breast cancer risk by removing a natural defense found in the fat cells of non-obese individuals.

Cancer immunotherapy offers long-term remissions but struggles with primary resistance, complex progression, and severe side effects. A landmark review in Science Bulletin highlights how multimodal AI integrates multi-scale data—from spatial omics and pathology to imaging and health records—to transform patient stratification. Tracing AI's evolution into foundation models and "virtual cells," the authors outline a clinical roadmap balancing efficacy, toxicity, and disease dynamics.